MRC1 and prostate cancer: Nanocarriers using Sia modified amphiphilic egg phosphatidylglycerol structure accumulated at the TAM rich site, enhancing ibrutinib effect and reducing off‐targeting.[57] Meanwhile Sia cyclodextrin carriers achieved complex TME in prostate cancer, delivering siRNA to TAMs, causing reprogramming.[58] Here we show that using glycans to target specific pattern recognition receptors expressed in macrophages such as CD206 and CD169 is a viable immunotherapy that can be used to treat liver diseases such as CRC hepatic metastases or PBC, two completely opposite pathologies.